What exactly changed in the March 13, 2026 Bernstein note for MOH?

Bernstein maintained an **Outperform** rating on March 13, 2026 but lowered the price target to **$173** due to a softer guidance from management. The MOH analyst rating stayed positive while the target was trimmed to reflect nearer-term pressures.

Does the maintained Outperform mean MOH is a buy now?

Maintained Outperform suggests analysts still expect outperformance, but investors should assess valuation, risk tolerance, and time horizon. The MOH analyst rating indicates confidence in the company, not a guarantee of immediate gains.

How should investors interpret the new $173 price target?

A lower price target usually reflects reduced near-term upside estimates. Use the **$173** target to gauge analyst expectations, then compare it with current market price, market cap **$7,684,572,500**, and your investment horizon.

Where can I read the full Bernstein note and tracking on MOH?

The Bernstein note summary is available via StreetInsider: [StreetInsider article](https://www.streetinsider.com/Analyst+Comments/Molina+Healthcare+%28MOH%29+PT+Lowered+to+%24173+at+Bernstein+on+%27Soft+Guide%27/26157389.html). For continuous coverage and our proprietary grade, see the Meyka MOH hub

Analyst Ratings

Bernstein Maintains Outperform on Molina Healthcare (MOH) March 13, 2026

ByHuzaifa Zahoor March 14, 2026March 14, 2026

Bernstein maintained an Outperform rating on Molina Healthcare, Inc. (MOH) on March 13, 2026, while lowering its price target to $173. The MOH analyst rating stay signals continued confidence in Molina’s strategic position despite a softer near-term guide that prompted the price target cut. Bernstein cited a “soft guide” as the primary driver for the target reduction. The update accompanied a modest market reaction of -0.11% ($-0.17) and reflects focused near-term caution, not a shift in long-term view.